Cencora

• 1. Merger And Rebranding

  ›

  The year 2001 marked a pivotal moment in American healthcare when two major pharmaceutical distributors merged to form AmerisourceBergen. David Yost served as the chief executive officer of AmeriSource Health Corporation before the deal and continued leading the combined entity afterward. This new company quickly grew into one of the largest pharmaceutical organizations globally, distributing generic drugs, over-the-counter products, and home care supplies across the United States. By 2019, the firm reported annual revenue exceeding $179 billion, ranking tenth on the Fortune 500 list. The organization maintained twenty-six distribution centers within the US alone, with nine additional facilities in Canada and four specialty units dedicated to complex medical needs. In August 2023, the company officially changed its name to Cencora and began trading under the ticker symbol COR on the New York Stock Exchange.

• 2. Global Logistics Network

  ›

  AmerisourceBergen operates through four primary business units including AmerisourceBergen Drug Corporation and World Courier, the latter being the world's largest specialty courier company for biopharmaceuticals. The acquisition of World Courier added more than 150 company-owned offices around the globe to their existing infrastructure. Their packaging production capacity exceeds one million square feet across both the US and UK operations. These logistics networks support acute care hospitals, independent pharmacies, mail-order facilities, physicians, clinics, nursing homes, and assisted living centers throughout America. Good Neighbor Pharmacy represents another key component, serving as a cooperative network of over 3,400 independently owned pharmacies sponsored by the parent company. This extensive reach allows them to handle approximately 20% of all pharmaceuticals sold and distributed within the United States each year.

• 3. Strategic Acquisitions

  ›

  The company pursued aggressive growth strategies through targeted acquisitions beginning in 2011 when they purchased IntrinsiQ for $35 million. Steven Collis replaced David Yost as CEO in July of that same year. March 2012 saw agreement to acquire World Courier Group Inc for $520 million, expanding their transportation capabilities significantly. January 2015 brought the purchase of MWI Veterinary for $2.5 billion followed by PharMEDium, a compounding drug company, for $2.58 billion later that October. On the 3rd of January 2018, AmerisourceBergen acquired H.D. Smith, described as the largest privately held national pharmaceutical wholesaler in the U.S. the 2nd of June 2021 marked the acquisition of Alliance Healthcare from Walgreens Boots Alliance for approximately $6.5 billion. The most recent major deal occurred on the 2nd of January 2025, when Cencora bought 85% of Retina Consultants of America for roughly $4.4 billion.

• 4. Pandemic Distribution Agreement

  ›

  June 2020 witnessed an unusual government arrangement regarding remdesivir, the first approved coronavirus treatment drug. The U.S. Department of Health and Human Services agreed to pay manufacturer Gilead's wholesale acquisition price while collaborating with state governments and AmerisourceBergen to allocate shipments directly to American hospitals through September 2020. During this timeframe, American patients received over 90% of Gilead's projected output exceeding 500,000 treatment courses. This agreement ensured critical access to life-saving medication during the early stages of the pandemic crisis. The collaboration demonstrated how large distributors could coordinate with federal agencies to manage emergency medical supply chains effectively under extraordinary circumstances.

• 5. Opioid Settlements

  ›

  West Virginia initiated legal action against AmerisourceBergen alleging contributions to the opioid epidemic by shipping excessive amounts of pain medication into the state. December 2019 saw Michigan become the first state to sue four opioid distributors including AmerisourceBergen under the Drug Dealer Liability Act. By May 2020, Oklahoma Attorney General Mike Hunter filed suit in Bryan County District Court claiming the company provided enough opioids for every adult resident there to receive 144 hydrocodone tablets each. January 2022 brought a landmark settlement where AmerisourceBergen, McKesson, Cardinal Health, and Johnson & Johnson agreed to pay $26 billion to resolve claims from all but five states. Had litigation proceeded to court, these companies faced potential penalties reaching up to $95 billion total. None of the participating companies admitted wrongdoing as part of this massive financial resolution covering 46 states plus Washington DC.

• 6. Fraud And Penalties

  ›

  October 2018 marked when AmerisourceBergen agreed to pay $625 million settling civil fraud allegations involving repackaged drugs and unapproved medications. The company had previously been found guilty of misdemeanor charges related to pre-filled syringes lacking FDA approval. A subsequent agreement added another $260 million payment bringing the total settlement amount to $885 million. Between January 2001 and January 2014, subsidiaries MII and OSC operated programs creating millions of pre-filled syringes distributed to oncology practices nationwide. At an Alabama facility called MII, drug products were removed from original glass vials and pooled in untested plastic containers before being extracted and repackaged into syringes. This process allowed the company to harvest overfill from multiple vials, creating more doses than originally purchased while retaining unopened vials for resale elsewhere. Over thirteen years, MII manufactured thousands of syringes daily eventually exceeding one million annually sold throughout the United States. Approximately 57% of patients receiving these injections were Federal Health Care Program beneficiaries generating profits between $2.3 and $14.4 million yearly totaling at least $99.6 million.